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Abstract
TRIMCyps are anti-retroviral proteins that have arisen independently in New World and Old World primates. All TRIMCyps
comprise a CypA domain fused to the tripartite domains of TRIM5a but they have distinct lentiviral specificities, conferring
HIV-1 restriction in New World owl monkeys and HIV-2 restriction in Old World rhesus macaques. Here we provide evidence
that Asian macaque TRIMCyps have acquired changes that switch restriction specificity between different lentiviral lineages,
resulting in species-specific alleles that target different viruses. Structural, thermodynamic and viral restriction analysis
suggests that a single mutation in the Cyp domain, R69H, occurred early in macaque TRIMCyp evolution, expanding
restriction specificity to the lentiviral lineages found in African green monkeys, sooty mangabeys and chimpanzees.
Subsequent mutations have enhanced restriction to particular viruses but at the cost of broad specificity. We reveal how
specificity is altered by a scaffold mutation, E143K, that modifies surface electrostatics and propagates conformational
changes into the active site. Our results suggest that lentiviruses may have been important pathogens in Asian macaques
despite the fact that there are no reported lentiviral infections in current macaque populations.
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Introduction
Mammals have evolved antiviral proteins called restriction
factors, which contribute to their protection from pathogenic viral
infections. Expression of restriction factors is invariably enhanced
by the innate immune cytokines of the type one interferon family
suggesting that restriction factors are an integral part of the innate
immune system [1]. Pathogenic viral infections are thought to be a
significant source of selective pressure on restriction factor
evolution. Evidence for positive selection is found in the sequences
of the intracellular antiviral restriction factors APOBEC3G,
TRIM5a and tetherin and the positively selected amino acids
have been shown to influence antiviral specificity [2-5]. Positions
under positive selection tend to be in patches on the protein that
directly contact the pathogen. Mutation of these residues alters
which viruses are restricted. Variability and evidence for positive
selection in regions of contact between host and pathogen illustrate
the evolutionary conflict during which both constantly evolve
under pressure from the other, with each alternately gaining the
advantage. This ongoing arms race is described by the Red Queen
hypothesis [6,7] which has also been elegantly demonstrated by
the study of bacteria/phage coevolution [8].
The restriction factor TRIM5a contains an N terminal tripartite
motif comprising RING, Bbox2 and coiled coil domains and a C
terminal PRYSPRY or B30.2 sequence that constitutes the virus-
binding domain [9–13]. TRIM5a exhibits potent species-specific
antiviral activity against retroviruses. This activity is mediated, in
part, by recruiting proteasomes to incoming retroviral capsids
leading to their premature uncoating and destruction [13–16].
This is observed as a potent and early block to viral DNA synthesis
by reverse transcription. TRIM5a dimers are thought to recruit to
the retrovirus via interactions between their B30.2 domain and
retroviral capsid molecules [17]. Patches of amino acids with
evidence for positive selection are found in the B30.2 domain in
exposed loops on the very end of the molecule [3,18]. The
differences between species variants of TRIM5a in this region
dictate antiviral specificity by determining which capsids can be
recruited. Similarly, sequence differences between the viral capsids
from various retroviruses, particularly in the exposed loop region
referred to as the cyclophilin binding loop, influence sensitivity of
the virus to restriction by TRIM5a, presumably by influencing the
ability of TRIM5a to bind [10–12,19].
TRIM5-CypA chimeric proteins, referred to as TRIMCyps,
have evolved through modification of the TRIM5 genetic locus on
PLoS Pathogens | www.plospathogens.org 1 August 2010 | Volume 6 | Issue 8 | e1001062two independent occasions during primate evolution. [20–26].
Retrotransposition events, indicated by typical target site duplica-
tions, have inserted complete CypA cDNA sequences into the
TRIM5 loci in different positions in New World owl monkeys and
Old World macaques. These modifications have caused replace-
ment of the virus binding B30.2 domain with a cyclophilin A
(CypA) cDNA (Fig. 1A) CypA is a ubiquitous and highly conserved
protein, whose sequence is identical in humans and macaques
[27]. However, the CypA sequences in owl monkey and macaque
TRIMCyps are not the same. Furthermore, like the parental
CypA domain, owl monkey TRIMCyp targets HIV-1 M and O-
group viruses but not HIV-2, whereas rhesus macaque TRIMCyp
targets HIV-2 and HIV-1 O group but not HIV-1 M group virus.
HIV-1 and HIV-2 are derived from zoonoses of different lineages
of primate lentivirus, HIV-1 from chimpanzees and HIV-2 from
sooty mangabeys [28,29]. HIV-1 O and M group viruses are also
distinct viruses, derived from different zoonotic transfers from
chimpanzees and with radically different frequencies in the human
population [29]. Recently, we showed that the change in lentiviral
specificity in rhesus macaque TRIMCyp is mediated by two
mutations at positions 369 and 372 (equivalent to positions 66 and
69 of the Cyp domain) that alter the conformation of the active site
[30]. From hereon we use the CypA numbering for example
TRIMCyp residue 369 is referred to as Cyp 66. Importantly,
previous work showed that TRIMCyp encoding a Cyp domain
changed at a single amino acid from the natural cyclophilin A
sequence (Cyp R69H) restricts a broader range of viruses,
including HIV-1 M and O groups and HIV-2 [30]. Since a
broad anti-viral specificity would confer a selective advantage, we
hypothesised that a TRIMCyp encoding this single change may be
present as a natural allele. Investigation of naturally occurring
TRIMCyp alleles in Asian Macaques reveals that an ancestral
TRIMCyp bearing this broad-specificity mutation (Cyp R69H)
has been specialised towards different lentiviruses in different
species, giving rise to distinct specificities in present day macaques.
Results
A TRIMCyp encoding the mutation R69H but not D66N in its
Cyp domain has previously been identified in Macaca fascicularis [24].
To characterise Macaca fascicularis TRIMCyp (Mafa TRIMCyp) we
R TP C Rc l o n e daT R I M C y pc D N Af r o mR N Ap u r i f i e df r o m
peripheral blood lymphocytes from an Indonesian Cynomolgus
macaque. The protein sequence of the Mafa TRIMCyp cDNA that
we amplified differed from that described by Brennan and colleagues
at 4 positions I77T, E209K, D247E, and H357R (CypH54R). We
refertoBrennan’salleleasMafaTRIMCyp1andtheallelewecloned
as Mafa TRIMCyp2. The protein sequences of the two Mafa
TRIMCyps are shown aligned to the rhesus macaque (Macacamulatta)
(Mamu) TRIMCyp and CypA protein sequences (Fig. 1).
In order to examine the antiviral specificity of Mafa
TRIMCyp2 we cloned it into a murine leukaemia virus (MLV)
based expression vector and expressed it in feline CRFK cells as
described [22]. These cells naturally encode a truncated TRIM5
and are thus highly permissive to VSV-G pseudotyped, GFP
encoding, lentiviral vectors and exhibit no detectable post-entry
restriction activity to retroviral vectors [31,32]. We infected the
Mafa TRIMCyp2 expressing CRFK cells with lentiviral vectors
derived from HIV-1, HIV-2, Simian Immunodeficiency Virus
from Tantalus monkeys (SIVtan) and Feline Immunodeficiency
Virus (FIV) as described [33,34]. CRFK expressing empty vector
were infected as a control and infected cells were enumerated
48 hours later by flow cytometry (Fig. 2A). Mafa TRIMCyp2
restricted HIV-1 and SIVtan but not HIV-2 infectivity. Mafa
TRIMCyp2 also restricted FIV infectivity. Furthermore, HIV-1,
SIVtan and FIV infectivity were rescued by adding the CypA
inhibitor cyclosporine (Cs) at 5 mM, as has been described [22,23].
We were surprised that Mafa TRIMCyp2 restricted HIV-1 and
not HIV-2 because a previous study has shown that Mamu
TRIMCyp protein encoding identical residues at Cyp domain
positions 66 (aspartate) and 69 (histidine) can restrict both viruses
[30]. Comparison of the Mafa and Mamu sequences (Fig. 1)
indicates that the Mafa TRIMCyp proteins differ from the Mamu
TRIMCyp sequence in the CypA domain at position Cyp 143,
encoding a lysine rather than a glutamate. We therefore mutated
the Mafa TRIMCyp2 to resemble the Mamu sequence at this
position (Cyp K143E) and expressed it in CRFK cells as before.
Cells expressing the MafaTRIMCyp2 Cyp K143E were able to
restrict both HIV-1 and HIV-2 by around 2 orders of magnitude
(Fig. 2B). This TRIMCyp mutant was also much more potent
against SIVtan infectivity. Treatment with 5 mM Cs partially
rescued HIV-1 and SIVtan infectivity and completely rescued
HIV-2 infectivity (Fig. 2B). We hypothesised that the Cyp E143K
(E446K) mutation specifically prevents binding of the HIV-2
capsid, whilst HIV-1 binding is unaffected. To test this, we
measured interaction between the HIV-1 and HIV-2 N-terminal
capsid domains and the CypA domains from the Mafa
TRIMCyp2 allele and K446E (Cyp K143E) mutant by isothermal
titration calorimetry (ITC). Whilst the K143E mutant bound both
HIV-1 and HIV-2, Mafa TRIMCyp2 was only able to bind HIV-
1 (Table 1). These data demonstrate that the Cyp E143K change
in Mafa TRIMCyp2 switches specificity from being able to bind
and restrict HIV-1 and HIV-2 to being able to bind and restrict
only HIV-1. Cyp E143K also influences antiviral specificity
against the African green monkey lineage virus SIVtan, restricting
it much more weakly than its ancestral TRIMCyp protein. This
change therefore influences antiviral activity against members of
three lineages of extant primate lentiviruses.
In a previous study comparison of the crystal structure of the N
terminal capsid domain of HIV-2 with HIV-1 indicated that the
Author Summary
Retroviruses have constantly been infecting mammals
throughout their evolution, causing them to evolve
defensive mechanisms to protect themselves. One of
these mechanisms utilises intracellular antiviral molecules
referred to as restriction factors. Restriction factor
sequences have changed through primate evolution,
suggesting an ongoing battle between retroviruses and
their hosts as described by the Red Queen hypothesis.
TRIM5 is an important restriction factor able to protect
some monkeys, but not humans, from HIV infection.
Certain monkeys have modified their TRIM5 genes by
swapping the virus binding B30.2 domain with a
cyclophilin A domain inserted into the TRIM5 locus by
retrotransposition. This leads to expression of a TRIMCyp
protein with antiviral activity against viruses, such as HIV-1,
that recruit cyclophilins. It appears that cyclophilin makes a
particularly flexible virus-binding domain able to restrict
divergent lentiviruses from primates as well as cats. Here
we characterise the molecular details of Cyclophilin-Capsid
interactions focusing on TRIMCyp proteins from Macaca
Fascicularis. Using a structure/function approach we can
show the molecular details of how adaptive changes in the
TRIMCyp sequence switch specificity between members of
different primate lentiviral lineages. Mapping these chang-
es onto the macaque phylogeny reveals a history of
TRIMCyp evolution that directs restriction to a variety of
diverse lentiviruses.
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the position equivalent to HIV-1 CA88 [30]. This underlies a
significant conformational difference between the CypA binding
loops of HIV-1 and HIV-2 capsids and dictates binding to
TRIMCyp variants, which in turn correlates with restriction
sensitivity. We therefore tested whether the alanine at CA88 also
dictated sensitivity to Mafa TRIMCyp. To do this we used a
previously described HIV-1 mutant in which the alanine at CA88
had been removed (HIV-1 CA-A88), and an HIV-2 mutant in
which the missing alanine has been inserted (HIV-2 CA+A88).
GFP encoding HIV-1 and HIV-2 mutant vectors were prepared
and used to infect CRFK cells expressing Mafa TRIMCyp2 and
cells bearing empty vector as a control (Fig. 2C). In fact, whilst
HIV-1 was sensitive to Mafa TRIMCyp2 the mutant with a
shorter CypA binding loop was unrestricted. Furthermore, Mafa
TRIMCyp2 restricted the HIV-2 mutant with an extra alanine,
whereas the wild type virus remained unrestricted. The HIV-1
mutant was as infectious as the wild type virus whereas the HIV-2
mutant with an extra alanine was around an order of magnitude
less infectious than wild type on feline cells bearing empty vector.
However, the switch in sensitivity to TRIMCyp on adding or
removing the extra alanine residue in these viruses is clear.
Furthermore, corresponding binding experiments by ITC support
the restriction data; the loss or gain of restriction sensitivity upon
addition or removal of A88 directly correlates with loss or gain of
binding (Table 1). Sensitivity to Mafa TRIMCyp is therefore
dictated by the sequence of the CypA binding loop with the
alanine at CA88 being an important determinant.
In order to understand the structural basis for these restriction
specificities we solved the crystal structure of the Mafa TRIMCyp2
Cyp domain in complex with the HIV-1 capsid N terminal
domain (NTD) (Table S1). As stated above, there are two amino
acid differences between the Cyp domain of Mafa TRIMCyp and
the genomic CypA sequence, R69H and E143K. Superposition of
the Mafa:HIV-1 complex with the previously solved wild-type
CypA:HIV-1 structure (1AK4) [35] reveals that the two Cyp
mutations (R69H and E143K) do not provoke large structural
rearrangements (Fig. 3A). This is in contrast to the two mutations
in Cyp from Mamu TRIMCyp (D66N and R69H) that have
previously been shown to create a large (.16 A ˚) rearrangement of
the active site loop around positions 66–69 (loop66–69) and switch
specificity of binding and restriction from HIV-1 M group to HIV-
2 [30]. Mafa TRIMCyp thus maintains binding to HIV-1 despite
the R69H mutation because it conserves the closed loop66–69
conformation observed in wild type CypA. The closed-loop
conformation allows interactions with capsid position CA88,
enabling several hydrogen bond interactions to be made, including
between the CA88 peptide nitrogen and the peptide oxygen from
G72 in Cyp and a water-mediated interaction between the peptide
oxygen of CA88 and Cyp residue H54. The loss of these
interactions resulting from removal of A88 from HIV-1 explains
Figure 1. Sequence comparison of CypA and TRIMCyps from
Macaca mulatta and Macaca fascicularis reveal differences in the
Cyp domain of species variants of TRIMCyps. (A) The protein
sequence of Macaca mulatta Cyclophilin A (Mamu CypA) AF023861 is
shown aligned to TRIMCyp from Macaca mulatta EU157763 and Macaca
fascicularis (Mafa) EU371638. The protein sequence of human CypA is
identical. MafaTRIMCyp1 was described by Brennan and colleagues [24]
and Mafa TRIMCyp2 FJ609415 is described herein. Similarity is shown
by: asterisk, identical residue; colon, conserved substitution; period,
semi-conserved substitution; gap, no conservation; dash, missing
residue. The core domains of the RING, B-box and coiled coil regions
are shown. Arrows denote positions considered in this study. CypA
positions 54, 66, 69 and 143 are homologous to TRIMCyp positions 357,
369, 372 and 446 respectively. (B) A cartoon showing TRIMCyp splicing.
TRIM5a is encoded by an 8 exon gene with 7 coding exons. In certain
Old World macaque species a TRIMCyp encoding gene is found in
which exons 7 and 8 are replaced by a cyclophilin A cDNA placed in the
TRIM5 locus by retrotransposition [22-26]. The TRIMCyp found in New
World owl monkeys in also shown [20,21]. In this case the CypA
sequence is in intron 7 causing replacement of exon 8 with CypA. The
different positions of the CypA encoding exons in owl monkeys and
macaques indicates independent evolution of Old World and New
World TRIMCyp genes. Coding exons are shown in black, non coding in
grey and the retrotransposed CypA cDNA is shown in red.
doi:10.1371/journal.ppat.1001062.g001
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TRIMCyp2 (Fig. 3A).
The E143K mutation is located in a helix outside of the active
site at the opposite end of the Cyp domain to R69H. How does
such a distant mutation impact on viral specificity? The Mafa
complexed structure shows that the change from a negatively
charged glutamate to a positively charged lysine at 143 causes a
knock on effect through the molecule which impacts on the
stereochemistry of the active site. Mutation to lysine at position
143 causes changes to the backbone of a neighbouring active-site
loop around P58 by attracting the peptide oxygen and flipping it
from its orientation in the wild-type CypA structure (Fig. 3A). This
propagates changes to other Cyp active-site residues, including
R148 that is coordinated by the P58 peptide oxygen in the wild-
type structure (Fig. 3A). The altered position of P58 releases the
side chain of R148, allowing it to interact with capsid residues
downstream of residue A88. The E143K mutation also modifies
the surface electrostatics (Fig. 3B) leading to a significant increase
in the positive charge of the active site. Surface electrostatics are
also shown for rhesus TRIMCyp and CypA for comparison.
E143K therefore impacts on viral specificity through propagated
conformational changes and long-range electrostatic effects.
HIV-1 binding is unaffected by the charge alterations
introduced by R69H and E143K (Fig. 3B), whereas binding to
HIV-2 is conferred by a reduction in positive charge (R69H) and
abrogated by an increase in positive charge (E143K). HIV-2 can
be made insensitive to these charge changes by introducing A88
into the capsid, resulting in susceptibility to Mafa TRIMCyp2.
Figure 2. Restriction specificity of TRIMCyps against HIV-1, HIV-2 and FIV. (A) Feline CRFK cells expressing empty vector (EV) or Mafa
TRIMCyp2 (TCyp2) were infected with GFP encoding VSV-G pseudotyped vectors derived from HIV-1, HIV-2, FIV or SIVtan as shown. White bars
represent titres in the presence of DMSO vehicle and black bars represent titres determined in the presence of 5 mM cyclosporine (Cs). (B) As above
except cells expressed the Mafa TRIMCyp2 Cyp mutant K143E (K446E in TRIMCyp). (C) CRFK cells expressing empty vector (white bars) or Mafa
TRIMCyp2 (grey bars) were infected with wild type HIV-1 or HIV-2 vectors or HIV-1 mutant missing CA residue A88 (HIV-1 –A88) or HIV-2 mutant
encoding an extra alanine at position 88 (HIV-2 +A88). (D) Mafa TRIMCyp expression levels in the CRFK cells were shown to be equal by western blot
detecting the N terminal haemagglutinin epitope tag. The membrane was stripped and reprobed detecting tubulin to ensure equal loading. Data are
representative of two independent experiments performed with independently prepared virus preps.
doi:10.1371/journal.ppat.1001062.g002
Table 1. Affinities of cyclophilin domain binding to N
terminal domain capsids, as measured by isothermal titration
calorimetry, are shown.
HIV-1 HIV-2 HIV-1-A88 HIV-2+A88 FIV
Mafa
TCyp2
12 mM no binding no binding 207 mM2 7 mM
Mafa
TCyp2
K143E
12 mM1 3 mM no binding 9 mM1 5 mM
doi:10.1371/journal.ppat.1001062.t001
Conformational Adaptation of Asian Macaque TRIMCyp
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mechanisms but that insertion of A88 confers an HIV-1 like
binding mode. To test this we solved the structure of HIV-2 with
an alanine inserted at position 88 (Table S1). The introduction of
A88 increases the structural dynamics of the HIV-2 CypA-binding
loop and allows it to adopt alternative conformations (Fig. 4A).
Importantly, this allows the main-chain nitrogen of the introduced
A88 to adopt an orientation that in HIV-1 permits hydrogen bond
interaction with cyclophilin residues G72 and H54 (Fig. 4B). These
hydrogen bond interactions are not affected by the E143K
mutation, explaining why HIV-2 with an inserted A88 is no longer
affected by the charge change. It is unlikely that these interactions
are normally possible in HIV-2, since it has a deletion at this
position and the preceding proline lacks a hydrogen on its amide
group. Position CA88 is therefore a critical determinant of
sensitivity even to mutations that are over 20 A ˚ away as in the
E143K Mafa TRIMCyp2 allele.
In contrast to Mafa TRIMCyp2’s ability to restrict HIV-1 the
Mafa TRIMCyp1 protein identified by Brennan and colleagues
was shown to not restrict HIV-1 [24]. Mafa TRIMCyp 1 and 2
differ at four positions including Cyp position 54. We therefore
tested whether this difference is responsible for Mafa TRIMCyp1’s
lack of anti-HIV-1 activity. We mutated Cyp H54 to arginine in
Mafa TRIMCyp2 and expressed it in CRFK cells. Infection of the
modified cells with HIV-1, HIV-2 and FIV derived GFP encoding
vectors indicated that Cyp H54R ablates Mafa TRIMCyp2’s
ability to restrict both HIV-1 and FIV, explaining the different
restriction activities (Fig. 5). HIV-2 is also unrestricted by Mafa
Figure 3. Crystal structure of the Mafa Cyp:HIV-1 N-terminal capsid domain complex. (A) A secondary structure representation of the
complex is shown (top left) together with a detailed view of the active site (top right). The detailed view shows a superposition with CypA side chains
from the HIV-1:CypA complex (1AK4) coloured green and the Cyp side chains from Mafa TRIMCyp2 coloured yellow. Interacting residues from the
HIV-1 CypA-binding loop are coloured orange. The secondary structure of Mafa Cyp is coloured yellow in the background. Cyp mutation E143K
propagates structural changes within the active site around P58 and R148. Position 88 in the HIV-1 capsid makes several key interactions indicated as
dashed lines, including via a water molecule (W1) conserved in both wild-type and E143K structures. Mutation R69H does not alter the backbone
conformation of the loop. Mutation E143K leads to some alteration of backbone (P58) and surrounding side-chains (R148). Position 88 in the HIV-1
capsid makes several key interactions indicated as dashed lines, including with a water mediated interaction via a water molecule conserved in both
wild-type and E143K structures. (B) Comparison of electrostatic surface potential of CypA and Cyp domains from Rhesus and Mafa TRIMCyps. The
effect of mutations R69H and E143K on the electrostatic surface potential of the Cyp active site is shown. Charges were calculated and mapped onto
the molecular surface using APBS and scaled from -20 to +20 kT e
21. Blue represents a positive charge and red negative.
doi:10.1371/journal.ppat.1001062.g003
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structure (Fig. 3A) explains this observation. The peptide oxygen
of CA88 makes a water-mediated interaction with cyclophilin
residue H54 (H357 in TRIMCyp). The importance of this
interaction is indicated by the fact that the water molecule is
conserved in both the wild-type (1AK4) [35] and E143K structures
(Fig. 3A).
In order to consider the differences in Asian Macaque
TRIMCyp sequence in the context of Asian macaque evolution,
we mapped the changes onto the recently described macaque
phylogeny [36] (Fig. 6). We assume that the CypA sequence
retrotransposed into the macaque TRIM5 locus was wild type.
TRIMCyp with a wild type CypA sequence has been shown to
restrict HIV-1 but HIV-2 only weakly [23,30]. Intriguingly, the
phylogeny suggests that the R69H mutation arose early in a
macaque common ancestor, conferring broad antiviral specificity
including against both HIV-1 and HIV-2. Following speciation
events giving rise to present day macaque species, subsequent
TRIMCyp mutations were either selected or underwent fixation.
D66N mutation may have arisen independently in two different
macaque species, Macaca mulatta and Macaca nemestrina. This is
suggested by the fact that the D66N change is not found in Macaca
fascicularis TRIMCyps (Fig. 1). D66N switches antiviral activity
from restriction of both HIV-1 and HIV-2 to restriction of HIV-2
only (Fig. 2). In contrast, the Macaca fascicularis TRIMCyp
sequence has acquired an alternate change, E143K, which
switches antiviral specificity from HIV-1 and HIV-2 to HIV-1
alone, the opposite direction to nemestrina/mulatta (Figs. 2–3). The
allelic diversity in present day macaque species represents
functional TRIMCyps of defined lineage-specificity, strongly
suggesting selection pressure from different lentiviruses.
Discussion
Here we have considered the restriction of HIV-1, HIV-2 and
SIVtan as well as the feline lentivirus FIV by TRIMCyp proteins
from Cynomolgus macaques (Macaca fascicularis). Analysis of
Figure 4. CypA-binding loop conformations in the HIV2 +A88 capsid structure. (A) The four copies of the capsid in the asymmetric unit
have been superposed and the main chain of the CypA-binding loop shown. In gray is the structure of the HIV-2 capsid without A88 inserted. (B)
Superposition of HIV1:CypA complex and HIV-2 +A88 capsid structures. The main-chain of the CypA-binding loop of HIV-1 is shown in gray and HIV-2
+A88 in yellow. Insertion of A88 into HIV-2 may allow hydrogen bond interactions between capsid residues H54 and G72 as seen in the HIV-1
complex.
doi:10.1371/journal.ppat.1001062.g004
Figure 5. Mutation H54R in the Cyp domain abrogates Mafa
TRIMCyp2’s antiviral activity against HIV-1 and FIV. Feline CRFK
cells expressing empty vector (EV) or Mafa TRIMCyp2 bearing Cyp
mutation H54R were infected with GFP encoding VSV-G pseudotyped
vectors derived from HIV-1, HIV-2 or FIV as shown. White bars represent
titres in the presence of DMSO vehicle and black bars represent titres
determined in the presence of 5 mM cyclosporine (Cs). The Cyp domain
mutation H54R found in Mafa TRIMCyp1 explains its described lack of
activity against HIV-1 [24]. Data are representative of two independent
experiments performed with independently prepared virus preps.
doi:10.1371/journal.ppat.1001062.g005
Figure 6. Mapping the differences in the TRIMCyp cyclophilin
sequences onto the macaque phylogeny suggests convergent
evolution of D66N and switching of antiviral specificity
between lentiviral lineages throughout Asian macaque evolu-
tion. The macaque phylogeny is shown with the changes marked on
the branches. The table indicates restriction specificity with crosses
indicating strong restriction. Restriction broadly correlates with Cyp-CA
binding (Fig. 2, Table 1) [30]. CypA binds HIV-1 strongly and HIV-2
weakly [30].
doi:10.1371/journal.ppat.1001062.g006
Conformational Adaptation of Asian Macaque TRIMCyp
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diversity of antiviral activity can be achieved using a cyclophilin A-
like domain to target lentiviral capsids. The antiviral activity of
TRIMCyps can be very specific, distinguishing between HIV-1
and HIV-2, which are members of different lentiviral lineages, as
well as between HIV-1 M and O group viruses, which are derived
from independent zoonoses of SIVcpz from chimpanzees to
humans [23,30]. TRIMCyps can thus distinguish between closely
related lentiviruses for example the HIV-1s, whilst also being able
to restrict distantly related lentiviruses, for example FIV. By
studying the details of the structural changes that underlie the
switching of antiviral specificity we can gain a better appreciation
of the flexibility of CypA-lentiviral interactions. The Cyp E143K
change found in the TRIMCyp from Cynomolgus macaques
(Macaca fascicularis) is surprisingly distant from the region of contact
between Cyp and the lentiviral capsids. Nonetheless, by propa-
gating structural changes across the molecule this change can
switch a Cyp capable of binding and restricting HIV-1 and HIV-2
to one that only restricts HIV-1. The selection of a mutation that
affects specificity through propagated changes is reminiscent of the
antibody immune response. Affinity maturation has been shown to
utilise distant indirect mutations to alter the specificity and affinity
of more generalized primary antibodies [37–39].
Remarkably, the potency of single amino acid changes in Cyp is
mirrored by the effect of single amino acid changes in the lentiviral
capsids. Altering HIV-1 or HIV-2 by a single amino acid can
switch either virus cleanly between exquisite sensitivity and
complete insensitivity to restriction by Mafa TRIMCyp2
(Fig. 2C). These observations reinforce the notion that there is a
fine balance between restriction and replication. We imagine that
the host, which evolves relatively slowly, can compete successfully
with rapidly evolving lentiviruses because it relies on a large
number of innate and adaptive pathways to combat viral infection.
The host can also make complex adaptive changes, illustrated for
example, by the exchange of the B30.2 viral binding domain for
CypA placed in the TRIM5 locus by retrotransposition.
There are three possible explanations for the present day allelic
distribution of TRIMCyp in macaque species. First, modern
macaque species may have originated from a common ancestor
that was multi-allelic. Incomplete lineage sorting during speciation
may then have given rise to the limited allelic diversity in each
species. A second possibility is that following speciation, each
species may have been placed under selection by a different virus,
causing fixation of different alleles with different viral specificities.
Finally, the macaque common ancestor may have had limited
allelic diversity, for instance the broad specificity R69H allele, and
different viruses subsequently fixed new mutations in emerging
macaque species. In this last scenario, the D66N mutation that
switches specificity to HIV-2, would represent convergent
evolution in M.nemestrina and M.mulatta. It is likely that a
combination of the above processes - selection and random
fixation - underlie present day species diversity.
Irrespective of the evolutionary sequence of events, the data
presented here illustrate that specific changes made in the Cyp
domain of TRIMCyp during Asian monkey evolution make
important, and surprisingly potent, alterations to its antiviral
specificity [23,30]. Given that the D66N, R69H and E143K
TRIMCyp mutations all affect viral specificity it is tempting to
speculate that the Mafa TRIMCyp1 allele with its H54R mutation
in its Cyp domain, though not active against the lentiviruses tested,
restricts viruses that we have yet to determine. Cyp position H54 is
an active site residue that forms a water-mediated interaction with
HIV-1 (Fig. 3A). A larger arginine side-chain could be expected to
form a similar interaction but without an intermediate water. This
makes H54R a good candidate for fixation through selective
pressure from a viral infection in the distant past, as is likely the
case for the other TRIMCyp mutations.
The conclusion that lentiviruses have exerted selection pressure
in Asian macaques presupposes that Asian macaques have lost the
selective virus, or viruses, permanently as there are currently no
extant lentiviruses described in these animals. However, we cannot
be certain that lentiviruses do not exist in Asian macaque
populations as they have not been surveyed systematically and
rare viruses may yet be found. The fossil record suggests that
macaques migrated across Europe around 5.5 mya [36], whilst
lentiviruses are known to have been present in European
lagomorphs for at least 12 million years [40,41], It is therefore
possible that lentiviruses may have undergone interspecies
transmission into macaques at around this time. In contrast, the
Asian macaque-tropic SIVmac appears to be a cross-species
transmission from sooty mangabeys that occurred in captivity and
was probably the inadvertent result of forced passage experiments
during investigation of kuru transmission [42,43]. It is difficult to
find evidence for the loss of a lentivirus from a species but it is clear
that the numbers of HIV-1 O group infected individuals declined
sharply between 1988 and 1998 in Cameroon, although the
frequency now appears stable [44]. The number of HIV-2 infected
individuals has also fallen suggesting that in time these viruses
could disappear altogether from the human population [45]. The
rarity of endogenous lentiviral sequences has suggested that
lentiviruses are relatively young compared to related retroviruses
that are commonly found as endogenous sequences but it may be
that they are simply less efficient at entering the germ lines of their
hosts [40,41,46]. Thus, our observations suggest that whilst
lentiviruses may not be present in current populations of Asian
macaques they may have been important pathogens in the past.
Of course, other, as yet unidentified, cyclophilin binding
pathogens could have contributed to the selective pressures driving
TRIMCyp evolution although the switches in primate lentiviral
specificity that we have described lead us to favour lentiviruses as
an important selective force.
In conclusion, the structural changes mediated by Cyp residue
E143K illustrate the remarkable adaptability of CypA as a viral
binding domain, providing the necessary flexibility to respond to a
rapidly changing pathogen. Seemingly innocuous scaffold muta-
tions such as Cyp E143K can propagate structural changes within
CypA, resulting in sufficient rearrangement of the active site to
potently alter viral restriction specificity. The ease with which the
conformation and hence specificity of CypA can be changed with
even a single mutation explains why it has been selected as a
targeting domain for a primate restriction factor. The character-
isation of the different TRIMCyp homologues and their alleles
present in the Macaca species – nemestrina, mulatta and fascicularis –
show that each TRIMCyp mutation has a direct structural,
thermodynamic and functional effect on the restriction of viruses
from three lentiviral lineages. This strongly suggests that these
mutations are not the effect of random drift, but instead that
primate TRIMCyps have undergone positively selected changes
that have impacted specifically on antiviral activity.
Methods
Cells and viruses and infectivity experiments
Feline CRFK cells were a gift from Yasuhiro Ikeda and were
maintained in DMEM (Invitrogen) with 10% FCS (Biosera). VSV-
G pseudotyped lentiviral vectors encoding GFP derived from
HIV-1 [47,48], HIV-2 [49] and FIV [50] were prepared as
described [51]. SIVtan with GFP in place of Nef was a gift from
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Viral mutants HIV-1 CA –A88 and HIV-2 CA +88A have been
described [30]. Infections were performed on 25000 cells/well in
24 well plates or 200,000 cells/well in 6 well plates. Serial dilutions
of virus were used to infect cells and the percentage of green cells
expressing GFP was measured 48 hours later by flow cytometry as
described [52]. Data are presented as mean titres derived from two
doses and errors are standard errors of the mean. Data are
representative of two independent experiments. Cyclosporine
(Sandoz) was diluted in DMSO and added to cells at the time of
infection at 5 mM. Viral doses were measured by reverse
transcriptase enzyme linked immunosorbant assay (Roche).
Cloning Mafa TRIMCyp2
RNA was purified from peripheral blood mononuclear cells
(PBMC) from an Indonesian Cynomolgus macaque (RNAeasy,
Qiagen) and reverse transcribed to cDNA (Superscript, Invitro-
gen). Mafa TRIMCyp was then cloned by PCR using pfu turbo
(Stratagene) into the murine leukaemia virus based vector EXN
[53], a gift from Paul Bieniasz. Three independent clones were
sequenced and the Mafa TRIMCyp2 sequence has Genbank
accession number FJ609415. MLV vector was prepared and
TRIMCyp expressed as described [22,34]. Mutagenesis was
performed as described [54]. EXN encodes an N terminal HA
tag allowing detection of protein expression by western blot,
detecting the HA tag.
Protein expression and purification
CA
N domains of HIV-1 M-type (NL4.3) and HIV-2 (ROD)
were expressed and purified as previously described [30]. The
CypA domain from MafaTRIMCyp was expressed as an N-
terminal His-tagged protein in BL21 (DE3) cells and protein
purified by capture on Ni-NTA resin (Qiagen) followed by gel
filtration. All mutant proteins were expressed and purified as per
the wild-type proteins.
Isothermal titration calorimetry
ITC experiments were conducted on a MicroCal ITC200.
Proteins were dialysed overnight against phosphate buffer (50 mM
KPO4 (pH 7.4), 100 mM NaCl, 1 mM DTT) and experiments
carried out at 15uC, with cyclophilin (typical concentration
1.4 mM) in the syringe and capsid (typical concentration
120 mM) in the cell. Binding isotherms were fitted using the
standard one-state model within the MicroCal instrument
software, as previously described [30].
Crystallography
Crystals of Mafa TRIMCyp2 CypA domain in complex with
HIV-1 CA
N were grown at 17 uC in sitting drops. Protein solution
(0.33 mM each of Mafa Cyp and HIV-1 CA
N in 20 mM HEPES
pH 7, 50 mM NaCl, 1 mM DTT) was mixed with reservoir
solution (30% PEG 6000, 1 M LiCl, 0.1 M HEPES pH 7, 0.5%
ethyl acetate) in a 1:1 mix, producing 0.2 mm 5 0.12 mm 5
0.02 mm crystals within 48 h. Crystals of HIV-2 CA
N +A88 were
grown at 17 uC in sitting drops. Protein solution (0.6 mM in
20 mM HEPES pH 7, 50 mM NaCl, 1 mM DTT) was mixed
with reservoir solution (2.8 M sodium acetate trihydrate pH 7, 3%
1,4-dioxane, 1% PEG 3350) in a 1:1 mix, producing 0.08 mm 5
0.04 mm 5 0.04 mm crystals within 48 h. Data was collected on
an in-house FR-E SuperBright high-brilliance rotating anode
linked to an automated crystal mounting system (ACTOR;
Rigaku). Data were processed and refined using programmes
from the CCP4 package [55]. Molecular replacement (Phaser) was
performed using structure 1AK4 [35] for the HIV1:Cyno complex
and the free HIV-2 structure [30] for the HIV-2 +A88 structure.
Figures were prepared using Pymol and the adaptive Poisson-
Boltzmann solver (APBS) for electrostatics.
Accession codes
Protein Data Bank: Coordinates for HIV-2 +A88 capsid mutant
and Mafa TRIMCyp Cyp domain in complex the HIV-1 CA have
been deposited with accession codes 2X82 and 2X83, respectively.
Mafa TRIMCyp2 sequence has Genbank accession number
FJ609415.
Supporting Information
Table S1 Data collection and refinement statistics
Found at: doi:10.1371/journal.ppat.1001062.s001 (0.04 MB
DOC)
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